Import from '@/components'

Hormonal IUD (Mirena/Kyleena) Food and Supplement Interactions: A Women's Health Guide

How the Hormonal IUD Actually Works (And Why It Matters for Interactions)

The levonorgestrel IUD releases progestin directly into the uterine cavity, making it fundamentally different from oral contraceptives. This local-first delivery is the reason food and supplement interactions are far less relevant here than they are for the pill.

Local vs. Systemic delivery

Mirena releases approximately 20 mcg of levonorgestrel per day initially, declining to roughly 10 mcg/day over 8 years. Kyleena starts at about 17.5 mcg/day. Compare that to the 150 mcg levonorgestrel in a standard combined pill. The IUD's serum concentrations remain so low that the primary contraceptive mechanism does not depend on systemic progestin levels the way an oral progestin does.

The three main contraceptive actions are:

• Cervical mucus thickening (the most immediately effective barrier)
• Endometrial suppression (reducing implantation viability)
• Partial suppression of ovulation in some users, particularly in the first year

Because the first two mechanisms are local, a substance that modestly lowers circulating levonorgestrel would need to dramatically alter intra-uterine drug concentrations to reduce effectiveness. There is no evidence any food or common supplement does this.

What CYP3A4 has to do with your IUD

Levonorgestrel is metabolized by hepatic CYP3A4. Strong CYP3A4 inducers (rifampin, certain anti-epileptics) accelerate its breakdown and are the reason oral LNG-containing pills fail at higher rates in women on those drugs. The question for IUD users is whether this matters when serum concentrations are already low. The FDA labeling for Mirena lists enzyme-inducing drugs as a theoretical concern, but ACOG Practice Bulletin No. 186 states that LNG-IUDs remain effective even in women taking enzyme-inducing medications, because the local mechanism is not dependent on systemic levels.

Foods and the Hormonal IUD: What the Evidence Says

No food has been shown to reduce levonorgestrel IUD effectiveness. Full stop. The reason this question comes up is legitimate: grapefruit inhibits CYP3A4, St. John's Wort induces it, and both affect oral hormonal contraceptives. But the IUD's pharmacokinetics change the calculus.

Grapefruit

Grapefruit and grapefruit juice inhibit intestinal CYP3A4, raising serum levels of many drugs. For oral contraceptives, this effect is real but clinically modest. For IUD users, the question is irrelevant to contraceptive protection. Even if grapefruit slightly raised circulating LNG, the local uterine mechanism is already providing protection independent of those serum levels. No clinical trials or pharmacokinetic studies have documented a meaningful grapefruit-LNG IUD interaction.

Soy and phytoestrogens

Soy contains isoflavones that bind estrogen receptors weakly. This generates frequent patient questions. Levonorgestrel acts on progesterone receptors, not estrogen receptors, so soy consumption does not interfere with IUD mechanism. Women with fibroids or endometriosis who are limiting soy for other reasons can do so without worrying about IUD protection.

High-fiber diets and absorption

Dietary fiber does not affect an intrauterine device. This matters because women sometimes recall reading that fiber reduces oral contraceptive absorption by binding estrogen in the gut. That mechanism requires gut absorption, which an IUD bypasses entirely. Eat your fiber.

Supplements and the Hormonal IUD: The Detailed Breakdown

Most supplements pose no real risk to IUD efficacy. A few deserve more nuanced attention.

St. John's Wort (Hypericum perforatum)

This is the supplement that warrants a real conversation. St. John's Wort is a well-documented CYP3A4 and P-glycoprotein inducer. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics found that St. John's Wort significantly reduced plasma levels of ethinylestradiol and norethindrone in oral contraceptive users. Breakthrough bleeding and pill failures have been reported.

For LNG-IUD users, no controlled study has demonstrated reduced efficacy. However, given the theoretical mechanism and the severity of the consequence (unintended pregnancy), most guidelines advise against combining St. John's Wort with any hormonal contraceptive. The Faculty of Sexual and Reproductive Healthcare (FSRH) guidance classifies St. John's Wort as a drug interaction concern for hormonal methods. For the IUD specifically, the local cervical mucus effect likely preserves adequate protection, but the data are not sufficient to guarantee this, and the risk-benefit calculation favors avoiding St. John's Wort if you are relying on the IUD as your sole contraceptive. Discuss alternatives with your clinician if you use St. John's Wort for mood support.

Magnesium

Magnesium does not interact with levonorgestrel pharmacokinetics. It is safe to take alongside an LNG-IUD. This comes up because magnesium is commonly recommended for menstrual cramps and PMS, both of which may continue (or even worsen transiently) after IUD insertion.

Vitamin C (ascorbic acid)

High-dose vitamin C raises estrogen levels in combined oral contraceptive users by inhibiting estrogen sulfation in the gut wall. Levonorgestrel IUDs do not contain estrogen, and the IUD bypasses gut metabolism entirely. Vitamin C at any dose does not affect LNG-IUD effectiveness.

Zinc and copper

Women sometimes ask whether zinc supplementation affects the IUD because they have heard of copper IUDs and know copper-zinc interactions exist metabolically. The LNG-IUD contains no copper. Zinc supplements do not interact with levonorgestrel pharmacokinetics.

Valerian root, melatonin, and herbal sleep aids

No pharmacokinetic interaction data exist for these herbs and LNG-IUDs. None are known CYP3A4 inducers at typical supplement doses. Until data exist, these are not a contraindication, but women should report all supplements to their prescribing clinician.

Ashwagandha and adaptogens

Ashwagandha (Withania somnifera) is sometimes described as having mild CYP3A4 inhibitory effects in vitro. Human pharmacokinetic data in women using LNG-IUDs do not exist. Given that inhibition (not induction) would theoretically raise, not lower, levonorgestrel levels, it does not pose an efficacy risk. Women taking ashwagandha for perimenopause-related fatigue or stress can continue doing so.

Iron supplementation

Women with Mirena or Liletta often see significant reductions in menstrual blood loss. The NEJM 2013 trial comparing LNG-IUS to usual care for heavy menstrual bleeding found the device reduced menstrual blood loss by 94% at 12 months versus 38% for usual care, with significantly better quality-of-life scores. Iron supplementation requirements typically decrease as bleeding reduces. If you were taking iron for heavy menstrual bleeding (HMB)-related anemia before device insertion, check ferritin levels 3 to 6 months after insertion. Your dose may need to be reduced.

Clinical framework for evaluating any new supplement with an LNG-IUD:

Ask three questions. First, is it a CYP3A4 inducer? If yes, flag it. Second, does it affect progesterone receptor binding? If yes, ask your clinician. Third, does it affect intrauterine drug concentrations directly? Almost nothing does, and no supplement has been shown to. If all three answers are no, the interaction risk is negligible.

Hormonal IUD Across Life Stages: How the Picture Changes

Reproductive years (ages 18 to 40)

The LNG-IUD is a first-line contraceptive option for this group per ACOG Practice Bulletin No. 186. Women with PCOS who choose the LNG-IUD for contraception gain an added benefit: endometrial protection. Women with PCOS have a higher lifetime risk of endometrial hyperplasia due to chronic anovulation and unopposed estrogen, and the progestin-releasing IUD addresses this locally. Supplement interactions in this group follow the general framework above.

Trying to conceive (pre-IUD removal)

The LNG-IUD does not impair future fertility. A prospective cohort study published in Contraception found that 80.5% of women attempting conception after LNG-IUD removal conceived within 12 months, comparable to non-IUD users. Women planning removal should stop any supplements that might theoretically affect cycle regularity (high-dose melatonin, for example) in the months before removal to allow natural cycle return.

Postpartum and lactation

The LNG-IUD is compatible with breastfeeding. Levonorgestrel transfers into breast milk at very low concentrations: less than 0.1% of the maternal dose reaches the infant through milk, and no adverse effects on infant growth, development, or milk supply have been demonstrated. ACOG and the World Health Organization both classify LNG-IUDs as appropriate for use from 4 weeks postpartum in breastfeeding women. Postpartum women taking galactagogues (fenugreek, domperidone) have no known interaction with the LNG-IUD.

Perimenopause (ages 40 to 55, irregular cycles)

The LNG-IUD has a specific and underappreciated role in perimenopause. Women using systemic estrogen therapy for perimenopausal symptoms need progestin to protect the endometrium. The 52 mg LNG-IUD (Mirena) is used off-label but with substantial evidence as the progestogen component of menopausal hormone therapy. A Cochrane review confirmed that the LNG-IUS provides effective endometrial protection when combined with systemic estrogen. This means a perimenopausal woman might be taking estradiol patches or gel alongside her IUD, and the interaction field now includes HRT formulations rather than just supplements. Transdermal estradiol does not interact with the IUD's local mechanism.

Perimenopausal women sometimes take black cohosh for hot flashes. Black cohosh is not a CYP3A4 inducer at standard doses and does not have a documented interaction with LNG-IUDs.

Post-menopause

Mirena is not indicated post-menopause as a standalone contraceptive (ovulation has ceased). Women who continue to use it for endometrial protection alongside HRT should note that the device's effective progestogen delivery spans its labeled duration regardless of hormonal status.

Pregnancy, Lactation, and Contraception Safety

Pregnancy: The LNG-IUD is contraindicated in confirmed pregnancy. If pregnancy occurs with an IUD in place, the device should be removed as early as possible. Retained IUDs in pregnancy carry risks of spontaneous abortion, preterm labor, chorioamnionitis, and septic abortion. Levonorgestrel has not been shown to cause fetal malformations in the small number of exposures documented in the literature, but the risks of device retention outweigh any benefit of leaving it in place. Women who conceive with an IUD in place must be evaluated urgently by a clinician and offered ectopic pregnancy exclusion, as the device reduces intrauterine pregnancy risk but does not eliminate ectopic risk.

Lactation: As noted above, LNG-IUD use during breastfeeding is safe and endorsed by ACOG and the WHO Medical Eligibility Criteria for Contraceptive Use. The extremely low systemic exposure compared to oral progestin-only pills makes it the preferred hormonal option during lactation for most women.

Contraception requirement: The LNG-IUD is itself a contraceptive. No additional contraceptive is required unless the device has been expelled (estimated expulsion rate approximately 3.1 to 5% in the first year), the strings cannot be located, or the device is past its labeled duration.

Who This Is Right For, and Who Should Reconsider

Women who are well-matched for the LNG-IUD

• Women who want long-acting, low-maintenance contraception without daily pill-taking
• Women with heavy menstrual bleeding or iron-deficiency anemia from HMB
• Women with endometriosis who need endometrial suppression alongside other treatments
• Women with PCOS who benefit from endometrial protection
• Perimenopausal women who need progestogen protection while using systemic estrogen
• Breastfeeding women who prefer highly effective contraception with minimal systemic exposure
• Women who take medications or supplements that would reduce oral contraceptive efficacy (with the caveat about St. John's Wort discussed above)

Women who should discuss alternatives or caution

• Women with active or recurrent pelvic inflammatory disease, or unexplained uterine bleeding before evaluation
• Women with a history of ectopic pregnancy (not an absolute contraindication, but warrants discussion given IUD-associated ectopic risk profile)
• Women with uterine anomalies that preclude correct device placement
• Women who are confirmed pregnant
• Women with current cervical or endometrial malignancy

The Evidence Gap: What We Do Not Know

Women have been underrepresented in pharmacokinetic trials for hormonal contraceptives, and supplement-contraceptive interaction research is particularly thin. The vast majority of data on supplement-drug interactions and hormonal contraception comes from studies on combined oral contraceptives, not IUDs. Most of what we know about supplements and LNG-IUDs is extrapolated from oral-pill data and in-vitro pharmacokinetics, not from trials specifically enrolling IUD users.

A 2020 review in Contraception found that fewer than 15% of contraceptive drug-interaction studies included women using long-acting reversible contraception. This gap matters. Women of color, women with obesity (where volume-of-distribution differences may affect systemic LNG levels), and women with PCOS are particularly underrepresented. Until better data exist, the clinical framework above offers the most rational approach to evaluating individual supplement questions.

Practical Guidance: What to Tell Your Clinician Before IUD Insertion or During Use

Bring a complete supplement list to your insertion appointment. Specifically flag:

• St. John's Wort (any dose, any formulation)
• Any supplement marketed as a "hormone balancer" (these sometimes contain herbal CYP3A4 modulators)
• High-dose melatonin if you are planning removal to try to conceive
• Any prescribed medications that are known enzyme inducers (phenytoin, carbamazepine, rifampin, topiramate at high doses)

For women in perimenopause adding HRT to an existing LNG-IUD, discuss the timing with your clinician. The IUD's progestogen activity should be considered when selecting the type and dose of systemic estrogen, because the combination determines total progestin exposure and endometrial protection adequacy.

The Menopause Society (formerly NAMS) recommends individualized assessment when LNG-IUD is used as the progestogen component of HRT, given variability in systemic LNG absorption across women.